Abstract
Patients receiving red blood cell (RBC) transfusions are at risk of iron overload, which can cause significant organ damage and is an important cause of morbidity and mortality. This study was an open-label, single-arm, prospective clinical study to evaluate the efficacy and safety of deferasirox (DFX) in patients with aplastic anemia (AA), myelodysplastic syndrome (MDS), or acute myeloid leukemia (AML). Patients with serum ferritin levels of at least 1000 ng/mL and ongoing transfusion requirements were enrolled. DFX was administered for up to 1 year. A total of 100 patients were enrolled. Serum ferritin levels decreased significantly following treatment (from 2000 to 1650 ng/mL, p = 0.004). The median absolute reduction in serum ferritin levels was -65 ng/mL in AA (p = 0.037), -647 ng/mL in lower-risk MDS (MDS-LR; p = 0.007), and -552 ng/mL in higher-risk MDS (MDS-HR)/AML (p = 0.482). Mean labile plasma iron (LPI) levels decreased from 0.24 μmol/L at baseline to 0.03 μmol/L at 1 year in all patients (p = 0.036). The mean LPI reduction in each group was -0.17 μmol/L in AA, -0.21 μmol/L in MDS-LR, and -0.30 μmol/L in MDS-HR/AML. Gastrointestinal disorders were commonly observed among groups (16.0%). DFX was temporarily skipped f...Continue Reading
References
Jun 1, 1984·American Journal of Clinical Pathology·R L HunterW R Vogler
Mar 1, 1995·Journal of Clinical Pathology·C Iglesias-OsmaS de Castro
Apr 1, 1994·Journal of Clinical Pathology·P HarrisonD Bareford
Feb 24, 2001·Seminars in Hematology·G M BrittenhamD E Farrell
Nov 28, 2001·Hematology·J P KushnerN F Olivieri
May 15, 2002·Evidence-based Mental Health·D Streiner, J Geddes
Jun 14, 2003·Blood·Breno P EspositoZ Ioav Cabantchik
May 25, 2004·Blood·Pensri PootrakulZ Ioav Cabantchik
Mar 2, 2005·Best Practice & Research. Clinical Haematology·Z Ioav CabantchikP Cianciulli
Dec 31, 2005·Pharmacological Reviews·Danuta S Kalinowski, Des R Richardson
Mar 30, 2007·European Journal of Haematology·Masaaki TakatokuUNKNOWN Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes
Jul 3, 2008·International Journal of Hematology·Yutaka KohgoJunji Kato
Feb 13, 2009·Current Medical Research and Opinion·Thomas E DeleaPradyumna D Phatak
Aug 12, 2009·Vox Sanguinis·A ShanderL T Goodnough
Sep 22, 2009·British Journal of Haematology·Giuliana ZanninelliZvi I Cabantchik
Oct 2, 2009·European Journal of Haematology·Hussam GhotiEli Konen
Feb 5, 2010·Leukemia Research·Christian RoseUNKNOWN GFM (Groupe Francophone des Myélodysplasies)
Apr 7, 2010·The Journal of Experimental Medicine·Celine CallensOlivier Hermine
Apr 28, 2010·Haematologica·Hussam GhotiEliezer A Rachmilewitz
May 11, 2010·Leukemia Research·Norbert GattermannUNKNOWN EPIC study investigators
Jun 11, 2010·Haematologica·Emanuela MessaDaniela Cilloni
Jun 23, 2010·Blood·Jong Wook LeeUNKNOWN EPIC study investigators
Jul 10, 2010·Leukemia Research·Peter L GreenbergCharles Schiffer
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan F ListEmmanuel Besa
May 29, 2012·Leukemia Research·E Fibach, E A Rachmilewitz
Citations
Aug 22, 2015·Leukemia Research·Florian NolteWolf-Karsten Hofmann
Dec 8, 2016·Expert Review of Hematology·Farhan Imran, Pradyumna Phatak
Jul 17, 2019·Blood Research·Sankalp Sharma
May 16, 2018·Journal of Cancer Research and Clinical Oncology·Florian NolteWolf-Karsten Hofmann
Jan 14, 2021·Cellular & Molecular Biology Letters·Shujuan ZhouSiqian Wang
Jan 26, 2021·Oxidative Medicine and Cellular Longevity·Feng RenJian Li
Mar 23, 2021·Pediatric Hematology and Oncology·Gizem Zengin ErsoyGönül Aydoğan